Julianne Smith

USPTO Granted Patents = 21 (Patent Applications = 20)

CIPO Patents = 6 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 13)

Average Co-Inventor Count = 4.3

ph-index = 4

Forward Citations = 83(Granted Patents)

Location History:

Paris, FR (2010)
New York, NY (US) (2019 - 2022)
Le Plessis Robinson, FR (2016 - 2024)

Company Filing History:

Years Active: 2010-2024

Loading Chart...

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11891614 - Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy (2024-02-06),

2. 11603539 - Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy (2023-03-14),

3. 11414674 - Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells (2022-08-16),

4. 11311575 - Methods for engineering highly active T cell for immunotherapy (2022-04-26),

5. 11304975 - Methods for engineering allogeneic and highly active t cell for immunotherapy (2022-04-19),

6. 11274316 - Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells (2022-03-15),

7. 11267892 - Chimeric antigen receptors targeting epidermal growth factor receptor variant III (2022-03-08),

8. 11077144 - CD19 specific chimeric antigen receptor and uses thereof (2021-08-03),

9. 11014989 - Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy (2021-05-25),

10. 11007224 - CD19 specific chimeric antigen receptor and uses thereof (2021-05-18),

11. 10874693 - CD19 specific chimeric antigen receptor and uses thereof (2020-12-29),

12. 10752670 - Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy (2020-08-25),

13. 10517896 - Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells (2019-12-31),

14. 10426795 - Use of preTalpha or functional variant thereof for expanding TCRalpha deficient T cells (2019-10-01),

15. 10378026 - RNA based method to obtain stably integrated retroviral vectors (2019-08-13),

Julianne Smith: Pioneering Innovator in Immunotherapy

Introduction:

Meet Julianne Smith, a brilliant innovator and inventor based in Le Plessis-Robinson, France. With an impressive total of 21 patents to her name, Smith has made remarkable contributions to the field of immunotherapy. Her latest patents involve methods for engineering allogeneic and immunosuppressive resistant T cells for more effective immunotherapy treatments. These groundbreaking inventions have the potential to revolutionize the treatment of cancer and viral infections.

Latest Patents:

Smith's latest patents focus on developing engineered T-cells that are both non-alloreactive (meaning they do not provoke an adverse immune response) and resistant to immunosuppressive drugs. Her method involves the precise modification of T-cells by inactivating the genes responsible for the immunosuppressive targets and the T-cell receptor. Specific rare cutting endonucleases, such as TALE-nucleases, are utilized to target crucial genes in the T-cells. This technique allows for the modification of T-cells from donors or cultured primary cells. Smith's inventions have the potential to make adoptive immunotherapy strategies more accessible and affordable for the treatment of cancer and viral infections.

Career Highlights:

Throughout her career, Smith has collaborated with esteemed companies in the biotechnology and pharmaceutical industries. She has extensively worked with Cellectis, a leading gene-editing company focused on developing innovative cellular therapies. Additionally, Smith has collaborated with Pfizer Corporation, one of the world's largest pharmaceutical companies, known for its commitment to advancing healthcare through groundbreaking research and development.

Collaborations:

In her groundbreaking work, Smith has collaborated with some notable colleagues, further highlighting her contributions to the field. Andrew M. Scharenberg, a renowned researcher and professor, has played a vital role in her research endeavors. Together, they have pushed the boundaries of immunotherapy treatments. Another key collaborator is Roman Galetto, an expert in gene-editing technologies, who has contributed immensely to Smith's innovative ideas and patents.

Conclusion:

Julianne Smith is a remarkable innovator who has significantly advanced the field of immunotherapy through her numerous patents and inventions. Her methods for engineering allogeneic and immunosuppressive resistant T cells have the potential to improve the effectiveness of immunotherapy treatments, offering new hope for patients battling cancer and viral infections. With her collaborations and extensive experience with renowned companies such as Cellectis and Pfizer Corporation, Smith's contributions to the field continue to shape the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.